This study aimed to understand the role of the matrix polysaccharide, hyaluronan (HA), in influencing the scarring process by assessing its impact on regulating fibroblast behavior. Donormatched human oral and dermal fibroblasts were used as models of nonscarring and scarring fibroblast phenotypes, respectively. Phenotypic differences in these two fibroblast populations were assessed and related to differences in HA synthesis and assembly. The two fibroblast populations showed intrinsic differences in their response to the profibrotic cytokine, transforming growth factor-␤ 1 (TGF␤ 1 ), in that oral fibroblasts were resistant to TGF␤ 1 -driven myofibroblastic differentiation. In dermal fibroblasts, differentiation was associated with an induction of HA synthase (HAS1 and HAS2) transcription and assembly of pericellular HA coats. In comparison, resistance to differentiation in oral fibroblasts was associated with failure of induction of HAS1 and HAS2 transcription and failure of pericellular coat assembly. Furthermore, inhibition of HA synthesis in dermal fibroblasts significantly attenuated TGF␤ 1 -mediated differentiation. Interleukin-1␤ stimulation resulted in induction of HAS1 and HAS2 transcription but did not induce phenotypic differentiation or induce HA coat assembly. In addition, neither overexpression nor down-regulation of HAS1 (the isoform uniquely deficient in nonscarring oral fibroblasts) influenced phenotypic differentiation. In conclusion, inhibiting HA synthesis modulates TGF␤ 1 -dependent responses in these cells preventing fibroblast to myofibroblast differentiation. Moreover, HA pericellular coat assembly, rather than HAS isoform expression, appears to be associated with phenotypic differentiation.
Progressive fibrosis of superficial tissues and internal organs can result in an array of clinical conditions ranging from disfigurement and progressive disability to end-stage organ failure and death. Fibrosis is a key component of numerous chronic diseases, including pulmonary fibrosis, chronic kidney disease, liver cirrhosis, and congestive cardiac failure, well known causes of worldwide death and disability (1) (2) (3) (4) (5) (6) . Despite this, there is a marked paucity of effective therapies targeting this process placing a considerable burden on health services.
Fibrosis can be considered as a form of aberrant wound healing in which there is progression rather than resolution of scarring. It results from unabated fibroblast activity leading to excessive accumulation of extracellular matrix (ECM) 3 causing disruption of normal tissue architecture and function. Fibroblasts are central to both the healing and the scarring processes and have distinct phenotypes depending on their site of isolation (7) . When activated, they undergo a number of phenotypic transitions and eventually acquire a contractile "myofibroblastic" phenotype characterized by the expression of ␣-smooth muscle actin (␣-sma) (8) . These myofibroblasts are responsible for closure of wounds and for the formation of the collagen-rich scar. In addition, their presence in tissues has been established as a marker of progressive fibrosis (9, 10) . The cytokine transforming growth factor-␤ 1 (TGF-␤ 1 ) is recognized as a mediator of wound healing, and its aberrant expression has also been widely implicated in progressive tissue fibrosis (9, 11, 12) . In addition to its direct effect on extracellular matrix turnover, it is known to drive fibroblast-myofibroblast differentiation and is capable of up-regulating ␣-sma in fibroblasts both in vitro and in vivo (13) (14) (15) .
Hyaluronan (HA) is a ubiquitous connective tissue glycosaminoglycan synthesized by HA synthase enzymes (HAS) of which three vertebrate genes have been isolated and characterized as follows: Has1, Has2, and Has3 (16, 17) . It has a role in maintaining matrix stability and tissue hydration. However, increased expression of this polysaccharide and its cell-surface receptor (CD44) has been detected in numerous fibrotic conditions associated with organ dysfunction (18 -22) . It is known to play a major role in regulating cell-cell adhesion (23) , migration (24 -26) , differentiation (27, 28) , and proliferation (29 -31) , and it therefore plays an important role in wound healing. In addition, it is involved in mediating cellular responses to TGF-␤ 1 . For example, our recent studies in epithelial cells have demonstrated that HA modulates TGF-␤ 1 signaling following interaction with its receptor, CD44 (32, 33) . We have demonstrated previously that phenotypic conversion of fibroblasts to myofibroblasts is associated with major changes in the production and * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 Both authors contributed equally to this work. 2 To whom correspondence should be addressed. Tel.: 442920748467; Fax:
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metabolism of HA (34) . Specifically, they have been shown to accumulate larger amounts of intracellular and extracellular HA and to assemble larger HA pericellular matrices. However, the functional significance of the alterations in HA turnover associated with the myofibroblastic phenotype remains unclear.
Healing of both oral mucosal and dermal wounds proceeds through identical stages of inflammation, proliferation, and remodeling of ECM. However, wound healing in the oral mucosa is clinically distinguished from dermal healing in terms of both its rapidity and lack of notable scar formation. Previous in vitro work has demonstrated that oral mucosal fibroblasts show increased migration, experimental wound re-population, and ECM re-organization compared with dermal fibroblasts (35, 36) . Consequently in trying to understand fibrosis, we have used dermal and oral mucosal fibroblasts as models of scarring and nonscarring fibroblast phenotypes, to identify the processes that underlie scar-free healing. In this study we first compared TGF-␤ 1 -dependent phenotypic regulation of the two fibroblast populations. Second, we compared the HA synthetic machinery both at base line and following TGF-␤ 1 activation. Finally, we assessed the role of HA in influencing differences in cell behavior.
The data presented here demonstrate that the different fibroblast populations show crucial differences in their response to the pro-fibrotic cytokine, TGF-␤ 1 . In addition, we have demonstrated that inhibiting HA synthesis modulates TGF-␤ 1 -dependent responses in these cells preventing fibroblast to myofibroblast differentiation.
EXPERIMENTAL PROCEDURES
Materials-All reagents were from Sigma unless otherwise stated. PCR and QPCR reagents and primers were purchased from Invitrogen and Applied Biosystems (Cheshire, UK).
Cell Culture-Four donor-matched samples of dermal and oral mucosal fibroblasts were obtained by biopsy from consenting adults undergoing routine minor surgery, and ethical approval for the biopsies was obtained from the South East Wales Research Ethics Committee. The cells were isolated as described previously (36) and cultured in Dulbecco's modified Eagle's medium and F-12 medium containing 2 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin supplemented with 10% fetal bovine serum (FBS) (Biologic Industries Ltd., Cumbernauld, UK). The cells were maintained at 37°C in a humidified incubator in an atmosphere of 5% CO 2 , and fresh growth medium was added to the cells every 3-4 days until confluent. The cells were incubated in serum-free medium for 48 h before use in experiments, and all experiments were done under serum-free conditions unless otherwise stated. All experiments were undertaken using cells at passage 6 -10.
Immunocytochemistry-Cells were grown to 70% confluence in 8-well Permanox chamber slides. The culture medium was removed, and the cells washed with sterile phosphate-buffered saline (PBS). For immunostaining of ␣-sma, the cells were fixed in acetone/methanol (1:1 v/v) for 5 min at room temperature. For staining of phalloidin, intended for visualization of filamentous actin, the cells were fixed in 3.5% paraformaldehyde for 15 min at room temperature and permeabilized with 0.1% Tween 20 in PBS, pH 7.3, for 5 min at room temperature. Following fixation, slides were blocked with 5% bovine serum albumin (BSA) for 20 min prior to a further washing step with PBS. Subsequently the slides were incubated with the primary antibody diluted in 0.1% BSA/PBS for 2 h at room temperature. Dilutions were as follows: murine monoclonal anti-␣-sma clone 1A4, final dilution 1:30; FITC-conjugated phalloidin, final dilution 1:50. Following a further washing step, slides were incubated with the appropriate conjugated secondary antibody for 1 h at room temperature as follows: FITC-rabbit anti-mouse IgG (DAKO, Cambridgeshire, UK) diluted 1:40 in 0.1% BSA/ PBS. Cells were then mounted and analyzed by fluorescent microscopy.
Conventional Reverse Transcription (RT)-PCR-RT-PCR
was used to assess HAS1 and ␣-sma mRNA expression in oral mucosal and dermal fibroblasts. The cells were grown to confluence in 35-mm dishes and washed with PBS prior to lysis with Tri-reagent and RNA purification according to the manufacturer's protocol. RT was performed using the random hexamer method. 1 g of RNA was added to 1 l of 100 M random hexamers, 2 l of 10ϫ PCR buffer, and 2 l of 0.1 M dithiothreitol. The solution was heated to 95°C for 5 min followed by 4°C for 2 min. 1 l of (40 units/l) ribonuclease inhibitor RNasin (Promega) and 1 l of (200 units/l) Superscript were added to each sample and mixed. The solution was incubated at 20°C for 10 min, 42°C for 40 min, and then 95°C for 5 min on a GeneAmp PCR System 9700. As a negative control RT was performed with sterile H 2 O replacing the RNA sample.
PCR was carried out in a final volume of 50 l/sample, 2 l of RT product, 37.25 l of sterile H 2 O, 25 pmol of each primer, 3 l of 10 mM dNTPs, 5 l of 10ϫ PCR buffer, and 0.25 units of AmpliTaq Gold. Thermal cycling was carried out using the GeneAmp PCR System 9700. Amplification was carried out using a cycle of 94°C for 40 s, 55°C for 60 s, and 72°C for 60s. As a negative control, PCR was performed with sterile H 2 O replacing the cDNA sample. PCR was simultaneously done for ␤-actin as a standard reference gene. After PCR, one-tenth of the PCR mixtures from the target gene and ␤-actin samples were mixed and separated by flatbed electrophoresis in 3% (w/v) NuSieve-agarose gels (Flowgen Instruments Ltd., Sittingbourne, UK), stained with ethidium bromide (0.5 mg/ml), and photographed using a Chemi Doc TM gel documentation system (Bio-Rad). Primer sequences shown in Table 1 . These experiments were also repeated using QPCR for confirmation.
Quantitative PCR-RT was performed as described above. PCR for HAS1, HAS2, and ␣-sma was performed using the The comparative C T method was used for relative quantification of gene expression. The C T (threshold cycle where amplification is in the linear range of the amplification curve) for the standard reference gene (ribosomal RNA) was subtracted from the target gene C T to obtain the ⌬C T (⌬C T ). The mean ⌬C T values for similar samples were then calculated. The expression of the target gene in experimental samples relative to expression in control samples was then calculated using Equation 1,
where ⌬C T (1) is the mean C T value calculated for the experimental samples, and ⌬C T (2) is the mean ⌬C T value calculated for the control samples.
Generation of HAS1-overexpressing Clone-HAS1 open reading frame (ORF) was a gift from Dr. Andrew Spicer (Texas A&M University, College Station, TX). Standard PCR was done to reproduce the ORF using Pfx50 DNA polymerase (Invitrogen) to increase the fidelity of the PCR product. The primers used in the reaction included sites for the restriction enzyme EcoRI. The ORF was inserted into the vector (pCR3.1) using a standard ligation reaction with Promega T4 DNA Ligase. Amplification of the cloned vector was done via bacterial transformation (JM109-competent Escherichia coli, Promega). The integrity and orientation of the HAS1 ORF were confirmed by restriction enzyme digestion (EcoRI) and sequencing (data not shown).
Transient transfection was performed with the aid of Nucleofector technology (Amaxa Biosystems) in accordance with the manufacturer's protocol for transfection of primary mammalian fibroblasts. Oral mucosal fibroblasts were grown to 70% confluence in T75 flasks. The medium was then removed, and the cells were harvested by trypsinization (solution containing 0.05% trypsin and 0.53 mM EDTA). Once the cells detached, the resulting cell suspension was treated with an equal volume of FBS to neutralize the protease activity. Cell counting was performed using a hemocytometer, and cell numbers were adjusted to a final concentration of 0.5 ϫ 10 6 cells/ml. The cells were then centrifuged (100 ϫ g for 10 min), and the resulting pellet was resuspended in basic nucleofector solution (BNS) (Amaxa Biosciences). The cells were transfected either with HAS1-pCR3.1 or pmaxGFP (green fluorescent protein) DNA. The utilized concentrations were 100 l of BNS to 1 g of DNA. The solution was then transferred to an Amaxa certified cuvette and placed in the nucleofector. Nucleofection was carried out for 5 s according to the pre-specified program designed for mammalian fibroblasts, and the cells were subsequently transferred to either 35-mm dishes or 8-well Permanox chamber slides containing pre-warmed medium supplemented with 10% FBS. The pmaxGFP vector was used as a positive control. Two negative controls were performed as follows: 1) 0.5 ϫ 10 6 cells in 100 l of BNS containing 1 g of DNA but without application of the program, and 2) 0.5 ϫ 10 6 cells in 100 l of BNS without DNA but with application of the program. The cells were incubated in medium supplemented with 10% FBS for 24 h followed by a 24-h incubation in serum-free medium prior to experimentation. pmaxGFP transfection was performed in parallel and used to calculate transfection efficiency (41.3% following 48 h and 39.1% following 96 h) (data not shown).
HAS1 siRNA Transfection-Transient transfection of dermal fibroblasts with specific siRNA nucleotides targeting HAS1 expression was performed using siPORT Amine transfection reagent (Ambion Ltd., Huntington, UK) in accordance with the manufacturer's protocol. Briefly, 3 l of transfection agent was diluted in 25 l of Opti-MEM reduced growth medium (Invitrogen) and left to incubate at room temperature for 10 min. Meanwhile, the specific HAS1 siRNA oligonucleotides were diluted in Opti-MEM reduced growth medium to give a final concentration of 20 M in a total volume of 25 l. The transfection agent mixture and siRNA mixture were then combined and incubated at room temperature for a further 10 min. The newly formed transfection complexes (50 l) were dispensed into empty wells of either 24-well culture plates or 8-well Permanox chamber slides. To each well, 4.5 ϫ 10 4 dermal fibroblasts were then added so that the total volume in each well was 500 l. As a control, cells were transfected with negative control siRNA (a scrambled sequence that bears no homology to the human genome). The cells were then incubated at 37°C with 5% CO 2 for 24 h in medium supplemented with 10% FBS followed by a 24-h incubation in serum-free medium prior to experimentation.
Visualization of Pericellular HA by Particle Exclusion Assay-The exclusion of horse erythrocytes was used to visualize the HA pericellular coat. Formalized horse erythrocytes were washed in PBS and centrifuged at 1,000 ϫ g for 7 min at 4°C. The pellet was resuspended in serum-free medium at an approximate density 1 ϫ 10 8 erythrocytes/ml. 500 l of this suspension was added to each 35-mm dish containing subconfluent cells and swirled gently for even distribution. The dishes were incubated at 37°C for 15 min to allow the erythrocytes to settle around the cells. Control cells were incubated with 200 g/ml bovine testicular hyaluronidase in serum-free medium for 30 min prior to the addition of formalized horse erythrocytes. On settling, the erythrocytes were excluded from zones around the cells with HA pericellular coats. This is viewed under the microscope as an area of erythrocyte exclusion. Zones of exclusion were visualized on a Zeiss Axiovert 135 inverted microscope. Because of the elongated shape of the cells, the exclusion zone at some areas of the cell was not visible. Therefore, the width of the exclusion zone was calculated at the widest point of the cell (usually the nucleus).
Analysis of 3 H-Radiolabeled HA-Cells were grown to full confluence in T75 flasks. The culture medium was then removed, and the cell was washed with PBS. Metabolic labeling was performed by incubation with 20 Ci/ml D-[
3 H]glucosamine hydrochloride for 24 h. The culture medium was then removed, and the cells were washed with PBS. The wash and medium were combined to form the conditioned medium extract. The conditioned medium extract was then treated with an equal volume of 200 g/ml Pronase in 100 mM Tris-HCl, pH 8, 0.05% sodium azide for 24 h. To remove any CD44-associated HA, the cells were treated with 10 g/ml trypsin in PBS for 10 min at room temperature; this was designated the trypsin extract. The trypsin extract was then treated with an equal volume of 200 g/ml Pronase for 24 h. The cells remaining in the culture flask were incubated directly with 100 g/ml Pronase for 24 h. The supernatant was decanted and designated the cell extract. Each extract was passed over DEAESephacel ion exchange columns equilibrated with 8 M urea in 20 mM BisTris buffer, pH 6, containing 0.2% Triton X-100. This removed any low molecular weight peptides and unincorporated radiolabel. HA was eluted in 8 M urea buffer containing 0.3 M NaCl. Each sample was split in two, and the HA was precipitated with 3 volumes of 1% potassium acetate in 95% ethanol in the presence of 50 g/ml of each HA, heparin, and chondroitin sulfate as co-precipitants. The first half of each sample was resuspended in 500 l of 4 M guanidine buffer and analyzed on a Sephacryl S-500 column equilibrated with 4 M guanidine buffer. To confirm that the chromatography profile generated was the result of radiolabeled HA, the second half of each sample was digested at 37°C overnight with 1 unit of Streptomyces hyalurolyticus hyaluronidase (ICN Pharmaceuticals Ltd.) in 200 l of 20 mM sodium acetate, pH 6, containing 0.05% sodium azide, and 0.15 M sodium chloride. The sample was then mixed with an equal volume of 4 M guanidine buffer and analyzed on the same Sephacryl S-500 column equilibrated with 4 M guanidine buffer. To produce the chromatography profile, the 3 H activity for each half of the sample was normalized and corrected for dilution, and then the hyaluronidaseresistant counts were subtracted. The chromatography profiles only depict hyaluronidase-sensitive activity in each fraction plotted against fraction number. . Cytotoxicity Assay-Cytotoxicity of 4-methylumbelliferone (4MU) was assessed by the commercial alamarBlue TM assay (BIOSOURCE), which is designed to measure cell viability and number. The assay utilizes an oxidation-reduction indicator that fluoresces in response to chemical reduction of growth medium resulting from cell growth and metabolism and dem- 2. ␣-sma mRNA expression in fibroblasts. Confluent monolayers of dermal and oral mucosal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with either serum-free medium alone (control) or serum-free medium containing 10 ng/ml TGF-␤ 1 , and the incubations were continued for 24 h. mRNA was extracted and cDNA prepared as described under "Experimental Procedures." ␣-sma Expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control, and gene expression was assessed relative to the control oral mucosal fibroblasts. The comparative C T method was used for relative quantification of gene expression (as described under "Experimental Procedures"), and the results are represented as the median Ϯ IQR of four donor-matched oral and dermal fibroblasts. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values, excluding outliers (o). Statistical analysis was performed using the Friedman test (p Ͻ 0.001 as shown) followed by the Wilcoxon Signed-Rank Test.
onstrates a linear relationship between the magnitude of fluorescence and cell number and viability. For this assay, subconfluent dermal fibroblasts were incubated for 24 h in serum-free medium alone or serum-free medium containing 1, 0.5, 0.4, 0.3, or 0.2 mM 4MU. Following 24 h, 10% alamarBlue was added to the medium for 1 h at 37°C. 100-l aliquots of the conditioned medium was removed and added to a clear 96-well plate, and fluorescence was measured in a FLUOstar Optima TM fluorescence meter (BMG LABTECH, Inc., Durham, NC), excitation wavelength 540 nm and emission wavelength 590 nm.
Statistical Analysis-The results are expressed as the mean Ϯ S.D. when normally distributed and median Ϯ interquartile range (IQR) when not normally distributed. The unpaired Student's t test was used for analysis of normally distributed data. For nonparametric data, the Friedman test was used for global comparison of different groups followed by the Wilcoxon Signed-Rank Test for subgroup analysis. All data were analyzed using software (SPSS 14.0 Chicago, IL), and p Ͻ 0.05 was considered significant.
RESULTS

Oral Fibroblasts Are Resistant to TGF-␤ 1 -mediated Myofibroblastic
Transformation-Under all conditions, dermal and oral mucosal fibroblasts constitutively expressed vimentin and were consistently negative for cytokeratin (data not shown). Under serum-free conditions, both dermal and oral mucosal fibroblasts were negative for ␣-sma staining (Fig. 1, A and C, respectively) . Stimulation of dermal fibroblasts with TGF-␤ 1 resulted in positive staining for ␣-sma (Fig. 1B) . In contrast, addition of TGF-␤ 1 to oral mucosal fibroblasts did not induce the expression of ␣-sma (Fig. 1D) .
Cytoskeletal re-organization of fibroblasts in response to TGF-␤ 1 stimulation was assessed with FITC-phalloidin staining, a fluorescent probe that binds filamentous actin. Under resting conditions, both dermal and oral mucosal fibroblasts displayed a small spindleshaped appearance (Fig. 1, E and H, respectively). Individual bundles of actin fibers were not seen, and the actin fibers formed a complex network mainly at the periphery of the cells. Following TGF-␤ 1 stimulation, dermal fibroblasts became larger and polygonal in shape. In addition, they demonstrated prominent cytoskeletal re-organization with the actin filaments coalescing to form large, thick bundles extending from end to end of cells (Fig. 1, F  and G) . In oral mucosal fibroblasts, a change in cell morphology was also demonstrated in response to TGF-␤ 1 stimulation. However, cytoskeletal re-organization was less prominent with less pronounced actin filaments and poorly developed stress fibers compared with the change seen in dermal fibroblasts (Fig. 1, H and J) . These findings were identical for all four patient samples assessed (data not shown).
Quantitative PCR demonstrated that under control and unstimulated conditions, dermal fibroblasts had significantly higher ␣-sma mRNA expression compared with patientmatched fibroblasts from the oral mucosa (p ϭ 0.002). Following TGF-␤ 1 stimulation, both dermal and oral mucosal fibroblasts up-regulated ␣-sma expression (p ϭ 0.002). Dermal fibroblasts, however, showed a median 13.2-fold increase in ␣-sma expression compared with a median of only a 5.9-fold increase in expression in oral mucosal fibroblasts in response to the same concentration and duration of TGF-␤ 1 stimulation (Fig. 2) .
HAS Isoform Expression-HAS1 was undetectable in both unstimulated dermal and oral mucosal fibroblasts using up to 40 PCR cycles. Stimulation with TGF-␤ 1 led to an induction of HAS1 expression in dermal fibroblasts; however, HAS1 remained completely undetectable in oral mucosal fibroblasts in response to the same concentration and duration of TGF-␤ 1 stimulation (Fig. 3A) . This lack of HAS1 expression was con- A, HAS1 mRNA expression in TGF-␤ 1 -stimulated fibroblasts. Confluent monolayers of dermal and oral mucosal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with either serum-free medium alone (control) or serum-free medium containing 10 ng/ml TGF␤ 1 , and the incubations were continued for 24 h. mRNA was extracted and cDNA prepared as described under "Experimental Procedures." HAS1 expression was assessed by RT-PCR, and ␤-actin was used as a standard reference gene. The PCR products were then separated by agarose gel electrophoresis. The results are triplicate measurements from the same patient and are representative of four patient-matched samples of dermal and oral mucosal fibroblasts. B and C, HAS2 mRNA expression in TGF-␤ 1 -stimulated fibroblasts. Confluent monolayers of dermal (B) and oral mucosal (C) fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with either serum-free medium alone (control) or serum-free medium containing 10 ng/ml TGF␤ 1 , and the incubations were continued for 24 h. mRNA was extracted and cDNA prepared as described under "Experimental Procedures." HAS2 expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control, and gene expression was assessed relative to the control samples. The comparative C T method was used for relative quantification of gene expression (as described under "Experimental Procedures"), and the results are represented as the median Ϯ IQR of four donor-matched oral and dermal fibroblasts. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values, excluding outliers (o). Statistical analysis was performed using the Wilcoxon Signed-Rank Test.
firmed by QPCR. HAS2 was detected in both unstimulated dermal and oral mucosal fibroblasts (Fig. 3, B and C, respectively) . However, although TGF-␤ 1 stimulation was associated with a significant up-regulation of HAS2 mRNA expression in dermal fibroblasts (Fig. 3B) (p ϭ 0.002) , it resulted in a significant down-regulation of HAS2 expression in oral mucosal fibroblasts (Fig. 3C ) (p ϭ 0.002). HAS3 expression was detected in both fibroblast populations; however, no significant difference in its expression was detected between the two cell types (data not shown).
Pericellular HA Coat Assembly-As differences in HAS gene expression had been demonstrated, pericellular HA accumulation was assessed using the exclusion of formalized erythrocytes. In this assay erythrocytes are excluded from the cell membrane of the fibroblasts by the large size and negative charge of any pericellular HA present. This is observed under microscopy as a zone of erythrocyte exclusion surrounding the cells. The results demonstrated that under unstimulated conditions neither fibroblast phenotype assembled a significant HA pericellular coat (Fig. 4, A and C) . In dermal fibroblasts, TGF-␤ 1 stimulation was associated with the assembly of a notable pericellular HA coat (Fig. 4B) . In contrast, oral mucosal fibroblasts did not assemble a pericellular HA coat in response to TGF-␤ 1 stimulation (Fig. 4D) . Taking measurements of the coat thickness at the widest point of 30 randomly chosen cells of each phenotype gave a mean thickness for the dermal fibroblast coat of 1. 
unpaired t test).
HA Is Causally Related to the Acquisition of a Myofibroblastic Phenotype-In light of the above results, depletion of the UDPglucuronic acid pool by 4MU was used to inhibit HAS enzyme function and determine the effects of this on dermal fibroblast phenotype. Metabolic labeling and size exclusion chromatography were used to establish 0.5 mM as the optimal effective concentration of 4MU, leading to a 50% inhibition of total HA production (data not shown). 0.5 mM was determined to be a nontoxic dose of 4MU as assessed by the alamarBlue cytotoxicity assay indicating over 90% cell survival at this dose (data not shown).
Quantitative PCR assessment demonstrated a significant reduction in ␣-sma mRNA expression in dermal fibroblasts incubated with TGF-␤ 1 in the presence of 4MU in all four patients (p ϭ 0.008) (Fig. 5) . Furthermore, FITC-phalloidin staining following TGF-␤ 1 stimulation of dermal fibroblasts revealed clear cytoskeletal re-organization (Fig. 6B) , which was not observed when TGF-␤ 1 was added in the presence of 4MU (Fig. 6C) . As further evidence, in the presence of 4MU, staining for the myofibroblast marker, ␣-sma, was significantly attenu- Confluent monolayers of dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with serum-free medium containing either 0.5 mM 4MU, 10 ng/ml TGF-␤ 1 , both 10 ng/ml TGF-␤ 1 and 0.5 mM 4MU, or serum-free medium alone (control), and the incubations were continued for 24 h. mRNA was extracted and cDNA prepared as described under "Experimental Procedures." ␣-sma expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control, and gene expression was assessed relative to control samples. The comparative C T method was used for relative quantification of gene expression (as described under "Experimental Procedures"), and the results are represented as the median Ϯ IQR of dermal fibroblasts from four different donors. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values, excluding outliers. Statistical analysis was performed using the Friedman test (p Ͻ 0.001 as shown) followed by the Wilcoxon Signed-Rank Test, and statistical significance was taken as p Ͻ 0.05. ated (Fig. 6E) when compared with cells stimulated with TGF-␤ 1 alone (Fig. 6D) .
Phenotypic Change Is Specifically Related to Alteration in Pericellular HA Coat Assembly-To investigate which components of the HA response may be responsible for fibroblast differentiation, we studied the effect of the pro-inflammatory cytokine, IL-1␤, a known inducer of HA synthesis and related this to changes in cell phenotype. Stimulation with TGF-␤ 1 was used as a positive control.
The results demonstrated that IL-1␤ induced HAS1 gene expression in dermal fibroblasts (Fig. 7A ), but HAS1 expression remained undetectable in oral mucosal fibroblasts (data not shown). HAS2 mRNA was expressed at base line by both cell types, and IL-1␤ stimulation induced HAS2 mRNA expression in both dermal (Fig. 7B ) and oral mucosal (Fig. 7C) fibroblasts. Subsequently, the effect of IL-1␤ stimulation on HA pericellular coat formation was assessed using the particle exclusion assay. Up-regulation of HAS1 and HAS2 expression through IL-1␤ stimulation did not induce HA pericellular coat formation in either dermal (Fig. 8B) or oral mucosal fibroblasts (Fig.  8D) .
To assess whether increased HAS1 and HAS2 mRNA expression associated with IL-1␤ stimulation correlated with phenotypic change, dermal fibroblasts were stimulated with IL-1␤ and ␣-sma mRNA expression assessed. IL-1␤ stimulation did not increase ␣-sma mRNA expression (Fig. 9A) . Consistent with this there was no change in ␣-sma protein expression as assessed by immunocytochemistry (Fig. 9B) .
A unique deficiency of HAS1 isoform expression was observed in the nonscarring oral mucosal fibroblasts (Fig. 3A) . To assess the significance of HAS1 expression in dermal fibroblasts, a time course study was performed to assess the relationship between HAS1 up-regulation in dermal fibroblasts and ␣-sma expression. The results illustrated that in dermal fibroblasts HAS1 was up-regulated as early as 3 h following TGF-␤ 1 stimulation, with marked up-regulation occurring up to 48 h following stimulation (Fig. 10A) . Expression of ␣-sma in the same samples, however, was up-regulated following 12 h of FIGURE 6 . Consequence of inhibition of HA synthesis on fibroblast phenotype. 70% confluent monolayers of dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with serum-free medium containing either 10 ng/ml TGF-␤ 1 (B and D), both 10 ng/ml TGF-␤ 1 and 0.5 mM 4MU (C and E), or serum-free medium alone (A), and the incubations were continued for 72 h. The cells were fixed and stained for FITC-phalloidin (A-C) or ␣-sma (D and E) as described under "Experimental Procedures." The cells were then mounted in Vectashield fluorescent mountant and viewed under UV light. Magnification is ϫ250.
FIGURE 7.
A, HAS1 expression in dermal fibroblasts following IL-1␤ stimulation. Confluent monolayers of dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The cells were then incubated in either serumfree medium alone (control, lane C), serum-free medium containing 2.5 ng/ml IL-1␤, or serum-free medium containing 10 ng/ml TGF-␤ 1 , and the incubations were continued for 3, 6, 12, or 24 h. TGF-␤ 1 stimulation was used as a positive control. mRNA was extracted and cDNA prepared as described under "Experimental Procedures." HAS1 expression was assessed by RT-PCR and ␤-actin was used as a standard reference gene. The PCR products were then separated by agarose gel electrophoresis. HAS2 expression in dermal (B) and oral mucosal (C) fibroblasts following IL-1␤ stimulation. Confluent monolayers of dermal fibroblasts (B) and oral mucosal (C) fibroblasts were growtharrested in serum-free medium for 48 h. The cells were then incubated in either serum-free medium alone (control), serum-free medium containing 2.5 ng/ml IL-1␤, or serum-free medium containing 10 ng/ml TGF-␤ 1 , and the incubations were continued for 12 and 24 h. TGF-␤ 1 stimulation was used as a positive control. mRNA was extracted and cDNA prepared as described under "Experimental Procedures." HAS2 expression was assessed by QPCR and ribosomal RNA expression was used as an endogenous control. The comparative C T method was used for quantification of gene expression relative to control samples at 12 h. FIGURE 8. Effect of IL-1␤ on HA-dependent pericellular matrices. Subconfluent layers of dermal (A and B) and oral mucosal (C and D) fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with medium containing either serum-free medium alone (A and C) or serum-free medium containing 2.5 ng/ml IL-1␤ (B and D), and the incubations were continued for 72 h. Formalized horse erythrocytes were then added to visualize the HA pericellular coat. Zones of exclusion were visualized using Zeiss Axiovert 135 inverted microscope. The cell bodies are denoted by black arrows. Original magnification was ϫ100.
TGF-␤ 1 stimulation and peaked following 24 h of stimulation (Fig.  10B) . To specifically assess the significance of this isoform in influencing fibroblast phenotype, HAS1 was then overexpressed in oral mucosal fibroblasts and down-regulated in dermal fibroblasts by means of transfection with the HAS1 expression vectors and HAS1 siRNA, respectively.
HAS1 overexpression in oral mucosal fibroblasts was confirmed by conventional RT-PCR (Fig. 11A ) and quantitative PCR (data not shown). However, no effect on ␣-sma mRNA (Fig. 11B ) or protein expression (data not shown) was observed in the HAS1-overexpressing oral fibroblasts as assessed by QPCR and immunocytochemistry. HAS1 down-regulation in dermal fibroblasts following transfection with siRNA was confirmed by QPCR (Fig. 12A) . The results demonstrated that HAS1 down-regulation had no effect on TGF-␤ 1 -mediated phenotypic differentiation as assessed by mRNA (Fig. 12B ) and protein expression (Fig.  12C ) of ␣-sma.
DISCUSSION
The regulation of cellular phenotype and differentiation during tissue injury is an important determinant of wound healing outcomes and the development of abnormal pathology. In fibrosis, it has long been established that the presence of ␣-smapositive myofibroblasts correlates directly with abnormal deposition of extracellular matrix and disease progression (8 -10) . In tissues, these myofibroblasts arise from activation and differentiation of stromal fibroblasts, a process in which TGF-␤ 1 has been strongly implicated (13, 14) . The data presented here demonstrate, for the first time, that fibroblasts derived from nonscarring oral mucosa demonstrate intrinsic differences to donor-matched dermal fibroblasts in terms of their ability to differentiate into myofibroblasts. This resistance to TGF-␤ 1 -mediated phenotypic differentiation in oral fibroblasts, alongside reports signifying that intra-oral wounds are associated with reduced inflammatory cell infiltrate and reduced cytokine gene expression (37) , aids in accounting for the scar-free wound healing that occurs in the oral mucosa. In contrast, dermal fibroblasts readily differentiate into myofibroblasts, and we have demonstrated that the linear polysaccharide, HA, plays a pivotal role in regulating this process of TGF-␤ 1 -driven cellular differentiation.
HA is a prominent constituent of fibrotic tissue; however, it has not been clear whether its presence is indicative of tissues undergoing reorganization and repair or whether it contributes directly to the fibrotic/scarring process leading to organ failure. A, ␣-sma mRNA expression in dermal fibroblasts following IL-1␤ stimulation. Confluent monolayers of dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The cells were then incubated in either serum-free medium alone (control, lane C), serum-free medium containing 2.5 ng/ml IL-1␤, or serum-free medium containing 10 ng/ml TGF-␤ 1 , and the incubations were continued for 12 and 24 h. TGF-␤ 1 stimulation was used as a positive control. mRNA was extracted and cDNA prepared as described under "Experimental Procedures. ␣-sma expression was assessed by RT-PCR, and ␤-actin was used as a standard reference gene. The PCR products were then separated by agarose gel electrophoresis. B, immunohistochemical analysis of dermal fibroblast phenotype in response to IL-1␤. 70% confluent monolayers of dermal fibroblasts were growth-arrested in serum-free medium for 48 h. The medium was then replaced with serum-free medium containing either 10 ng/ml TGF-␤ 1 , 2.5 ng/ml IL-1␤, or serum-free medium alone, and the incubations were continued for 72 h. TGF-␤ 1 stimulation was used as a positive control. The cells were fixed and stained for ␣-sma as described under "Experimental Procedures." The cells were then mounted in Vectashield fluorescent mountant and viewed under UV light. The results are representative of four patient-matched samples of dermal fibroblasts. Original magnification was ϫ250. Furthermore, previous work has demonstrated that it may be involved either in the maintenance of homeostasis or in the development of pathological events, depending on the context in which it is generated and packaged (33, 38 -40) . Our work has shown that dermal fibroblast differentiation was associated with increased HA synthesis and assembly of HA pericellular coats. In comparison, resistance to phenotypic change in the oral mucosal fibroblast population was associated with failure of induction of HA synthesis and failure of pericellular coat assembly. To investigate the functional consequences of these differences, we studied the effect of the HAS enzyme inhibitor, 4MU, on TGF-␤ 1 -mediated myofibroblastic differentiation in dermal fibroblasts. Depletion of the UDP-glucuronic acid pool by 4MU has been shown to inhibit HA synthesis and pericellular HA coat formation in a number of cell types, including fibroblasts (34, (41) (42) (43) (44) . Incubation of dermal fibroblasts with 4MU significantly attenuated both mRNA and protein expression of ␣-sma and resulted in limited cytoskeletal reorganization of filamentous actin. The resulting response to TGF-␤ 1 stimulation was comparable with the response seen in oral mucosal fibroblasts. Consequently, we propose that increased HA associated with fibroblasts may promote differentiation into myofibroblasts and therefore facilitate the formation of scar tissue and promote the fibrotic response.
Previous work has suggested that specific HA synthase isoform activity plays an essential role in instigating cell differentiation. HAS2 adenoviral transfection in Madin-Darby canine kidney epithelial cells and MCF-10A human mammary epithelial cells has been associated with the development of mesen- FIGURE 11 . A, HAS1 expression in oral mucosal fibroblasts. Total mRNA was extracted from nontransfected and HAS1-overexpressing oral mucosal fibroblasts 48 h after transfection. RT-PCR was performed as described previously, and the PCR products were separated by agarose gel electrophoresis. As a negative control, PCR was performed with RNA that had not undergone RT to detect contamination with plasmid DNA. B, ␣-sma mRNA expression in nontransfected and HAS1-overexpressing oral mucosal fibroblasts. Total mRNA was extracted from nontransfected and HAS1-overexpressing oral mucosal fibroblasts 48 h after transfection. ␣-sma expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control, and gene expression was assessed relative to nontransfected samples. The comparative C T method was used for relative quantification of gene expression (as described under "Experimental Procedures"), and the results are represented as the median Ϯ IQR of oral fibroblasts from three separate cultures. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values, excluding outliers. Statistical analysis was performed using the Wilcoxon Signed-Rank Test, and statistical significance was taken as p Ͻ 0.05. FIGURE 12. HAS1 (A) and ␣-sma (B) expression in HAS1-siRNA-transfected dermal fibroblasts is shown. Total mRNA was extracted from dermal fibroblasts following transfection with HAS1 or negative control (scrambled) siRNA and incubated in medium supplemented with 10% FBS for 24 h. The medium was then replaced with serum-free medium for 24 h. The cells were then incubated in either serum-free medium alone (control) or serum-free medium containing 10 ng/ml TGF␤ 1 for 24 h. HAS1 (A) or ␣-sma (B) expression was assessed by RT-QPCR. Ribosomal RNA expression was used as an endogenous control, and gene expression was assessed relative to control-scrambled samples. The comparative C T method was used for relative quantification of gene expression (as described under "Experimental Procedures"), and the results are expressed as the mean Ϯ S.D. for separate cultures of dermal fibroblasts. C, immunohistochemical analysis of dermal fibroblast phenotype following HAS1 siRNA transfection. 70% confluent dermal fibroblasts were transfected with HAS1 or negative control (scrambled) siRNA and incubated in medium supplemented with 10% FBS for 24 h. The medium was then replaced with serum-free medium for 24 h. The cells were then incubated in serum-free medium containing 10 ng/ml TGF␤ 1 for 72 h. The cells were then fixed and stained for ␣-sma, mounted in Vectashield fluorescent mountant, and viewed under UV light. Original magnification was ϫ250.
chymal and malignant characteristics (28) . This is in concordance with previous in vivo work demonstrating that HAS2 inactivation in mice embryo is lethal because of failure of cardiac endothelial cells to undergo epithelial to mesenchymal transition (27) . In addition, overexpression of different HAS isoforms has been linked to opposing cellular responses. HAS3 overexpression in a human kidney proximal tubular epithelial cell line was associated with a disease-limiting phenotype leading to an attenuation of macrophage-driven cell activation by TGF-␤ 1 (40) . In contrast, HAS2 overexpression led to the formation of pronounced pericellular HA coats that enhanced cell motility, a key early stage in epithelial to mesenchymal transition (39) . In our fibroblast populations, phenotypic differentiation in dermal fibroblasts was associated with an induction of HAS1 and HAS2 mRNA expression. In contrast, resistance to phenotypic differentiation in the nonscarring oral mucosal fibroblast population was associated with a unique failure of induction of HAS1 expression and a down-regulation of HAS2 expression. These findings led us to test the hypothesis that HAS1 and HAS2 isoform activities were also important factors in driving fibroblast differentiation. We consequently used IL-1␤ stimulation to determine whether induction of HAS1 and HAS2 transcription was a prerequisite for this process of differentiation. IL-1␤ is a pro-inflammatory cytokine implicated in the wound healing process and demonstrated to be a potent stimulus for HA synthesis in numerous cell types (45) (46) (47) . Stimulation with this cytokine in dermal cells was associated with an up-regulation of HAS1 and HAS2 mRNA expression similar to the response seen with TGF-␤ 1 stimulation. However, the induction of HAS1 and HAS2 transcription demonstrated with IL-1␤ did not result in up-regulation of ␣-sma expression or lead to phenotypic differentiation. Therefore, our hypothesis that HAS isoform activity was a possible requisite for phenotypic change appeared to be invalid. A unique deficiency of the HAS1 isoform was observed in the nonscarring, nondifferentiating oral fibroblasts. To specifically determine the significance of HAS1 expression in dermal fibroblasts, the relationship between HAS1 and ␣-sma induction was assessed in a time course experiment of TGF-␤ 1 stimulation. This showed that HAS1 up-regulation occurred earlier than ␣-sma, suggesting that it may be important in driving the induction in ␣-sma expression. However, when we specifically examined the effect of manipulating expression of this isoform on cell phenotype, in concordance with the previous results, neither HAS1 overexpression in oral fibroblasts nor HAS1 down-regulation in dermal fibroblasts appeared to influence TGF-␤ 1 -driven differentiation. This therefore suggests that HAS1 merely represents one of the many downstream targets of TGF-␤ 1 and does not modulate ␣-sma expression. Although HAS2 isoform expression was detected in both these fibroblast populations, TGF-␤ 1 stimulation had opposing effects on HAS2 transcription. In view of these results and in light of previous research relating to the HAS2 isoform (27, 28, 39) , future work may also need to be directed toward examining the role of this isoform in fibroblast differentiation.
The other striking disparity between the two fibroblast populations was in their ability to generate pericellular HA coats. Dermal fibroblast differentiation was associated with the assembly of pericellular HA coats, whereas resistance to differentiation in oral mucosal fibroblasts was associated with failure of HA coat assembly. The interpretation of these findings may be aided by recent data suggesting that the role HA plays is in part determined by its packaging into extracellular coat or cable-like structures. In several cell types the pericellular HA coat has been associated with cell proliferation and migration and is prominent during processes such as inflammation, wound healing, tumor invasion, and epithelial-mesenchymal transition (28, 31, 48 -50) . Transition to the myofibroblastic phenotype in lung fibroblasts has also been associated with increased HA pericellular coat assembly (34) . HA may also be packaged into cable-like structures that have been shown to bind mononuclear leukocytes via their cell surface CD44 resulting in attenuation of monocyte-dependent TGF-␤ 1 generation and thereby promoting tissue homeostasis (51) . To determine whether the formation of a HA pericellular coat was linked to fibroblast differentiation, we assessed pericellular coat assembly following IL-1␤ stimulation. In contrast to the response seen with TGF-␤ 1 , IL-1␤ stimulation did not result in the generation of a HA pericellular coat. This suggests that regulating HA pericellular coat formation, rather than HA synthase isoform activity, may be the crucial step in determining fibroblast differentiation.
The HA coat is a hydrated pericellular matrix that has been shown to modify cellular interactions with other matrix components and neighboring cells and has been associated with migratory capacity of cells. It is thought to be formed by newly synthesized HA polymers tethered to the HAS enzymes on the plasma membrane and bound to HA-binding proteins in the matrix. Recent data from Kulti et al. (42) has demonstrated that in several cell types, the HA coat can induce and maintain prominent microvilli in cell plasma membranes that rest on filamentous actin. These microvilli were degraded when the pericellular coat was destroyed and were dependent on an intact actin cytoskeleton. It is therefore interesting to speculate that the pericellular coat may be influencing cellular differentiation through direct interaction with the actin cytoskeleton.
There is a current focus on the role of HA-binding proteins or hyaladherins such as inter-␣ inhibitor, tumor necrosis factor-␣-stimulating gene-6 (TSG-6), and versican in regulating extracellular HA matrices. Recent data suggest that the balance between these hyaladherins maintains an equilibrium that regulates the assembly of the pericellular coat, and it has been suggested that changes in this equilibrium determines the packaging of HA into either coats or cables (39, 40) . Therefore, a possible future means of regulating fibroblast phenotype may be through regulating pericellular coat assembly through manipulation of these H-binding proteins.
In summary, the data presented demonstrate that increased HA in fibroblasts may facilitate the fibrotic response through promotion of TGF-␤ 1 -driven fibroblast differentiation and is consistent with previous reports suggesting that the HA pericellular coat may be involved in disease progression.
